drugset / Trial / NCT05611593

Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia

NCT05611593

Phase 1 Unknown 90 enrolled Follicle Pharma Ltd
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The CSP-001-FOL1 clinical study is aimed to investigate whether local topical administration of FOL100 lotion will be safe for the patient and will not cause local or systemic skin or other adverse events. It is also aimed at indicating effectiveness as compared with oral Finasteride 1mg. In this non-blinded study, each patient will choose his preferred arm (oral finasteride or FOL100 location). During the study, safety and efficacy will be measured as well as usability.

Timeline

Start
2022-10-20
Primary completion
2024-12
Completion
2025-02

Drugs

EvaluationDrugModalityDoseRoute
Subject FOL100 Unknown Topical
Comparator Finasteride Small molecule 1 mg Oral

Indications